Cat. No.: DAB-0012057
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human GCLC protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GCLC |
| UniProt No. | P48506 |
| Gene ID | 2729 |
| Gene Description | Glutamate-cysteine ligase catalytic subunit catalyzes the ligation of glutamate and cysteine, the first and rate-limiting step in glutathione biosynthesis. Studies show that deubiquitinases protect cancer cells when glutathione synthesis is suppressed. Upon inhibition of both GCLC and deubiquitinases, cancer cells undergo proteotoxic stress, leading to cell death. In addition, deletion of Gclc enhances reactive oxygen species in mouse regulatory T cells. Glutathione synthesized in part by Gclc is required for the suppressive function of mouse Tregs. Furthermore, in non-small cell lung cancer cell lines, the transcription factor NRF2 stimulates GCLC expression. When NSCLC cells are starved for cysteine, GCLC, through its non-canonical activity, catalyzes the synthesis of γ-glutamyl-peptide, therefore reducing glutamate levels to protect cells against ferroptosis. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
